In the short term, taking part in a clinical study has obvious benefits to the participant. Free food, a possible rent break, time to study, remuneration and some good old fashioned peace and quiet, away from the maddening chaos of the outside world. Hands up, who thinks about where this medication will be in a few years’ time?
You don’t need to be a scholarly subscriber of Science weekly to find out what’s happening, a quick trawl of the inter-web turns up some fascinating discoveries. Here are some shining examples from around the globe of revolutionary advancements to modern medicine, which will be bettering the lives of our species from here on in.
Johnson & Johnson’s investigational psoriasis drug guselkumab has achieved an 85.1% success rate with patients achieving cleared or minimal disease after 16 weeks. 80.2% of guselkumab patients had 90% skin clearance compared to only 53% for the Humira arm which is currently the best-selling drug in the world. Touch wood, they may be onto a serious game changer here.
Curing the incurable
Notoriously stubborn hepatitis C may have met its match. Treatment has historically only managed around a 70 percent cure rate. As a nasty addition to the treatment, sufferers are often subjected to debilitating side effects including chronic fatigue, fever and depression. New kid on the block Sofosbuvir, is a much more forceful nemesis of hep C, with success in as many as 95% of patients. Incredibly, the medication only needs to be administered for 12 short weeks as opposed to the lengthy stage time of its predecessor which can be needed for up to a year.
DBV Technologies announced remarkable results for Viaskin Peanut at the end of 2016. The treatment involves the use of a non-invasive skin patch, it has shown to increasingly improve symptoms of peanut allergy in 6 to 11-year old children at risk of death due to accidental exposure to the allergen. The next phase of trial is underway with results expected in the next 12 months.
Final test results have confirmed that an experimental Ebola vaccine, developed by the Canadian government in a Winnipeg, is proving it’s effectiveness. The vaccine, called rVSV-ZEBOV, was studied in a trial involving more than 11,000 people in Guinea. Of the 5837 participants who received the vaccine, no Ebola cases were recorded 10 days after vaccination.
Of course, we’re not saying we were involved in the miracles of science presented here, we just love a good breakthrough. Watch this space.